SCHEMBL6797332

SCHEMBL6797332

CCOC(=O)c1cc2c(C(F)(F)F)cc(OCP(=O)(OCC)OCC)cc2n1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
KDM4E B2RXH2 5/20 0.34
ALOX5 P09917 2/20 0.34
ATF1 P18846 1/20 0.34
NFKB1 P19838 1/20 0.34
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
LDHA P00338 1/20 0.32
MAOA P21397 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797140 0.83 ALOX5 (0.37) KDM4EALOX5ALDH1A1SMN1; SMN2NPC1
SCHEMBL6796884 0.83 AGER (0.40) POLBGAAKDM4EALOX5ALDH1A1
SCHEMBL6799072 0.83 GAA (0.41) POLBGAAKDM4EALOX5ALDH1A1
SCHEMBL6799070 0.83 POLB (0.41) POLBGAAKDM4EALOX5ALDH1A1
SCHEMBL6800234 0.82 KDM4E (0.37) KDM4EALOX5ALDH1A1SMN1; SMN2NPC1
SCHEMBL6796807 0.82 KDM4E (0.34) KDM4EALOX5ALDH1A1SMN1; SMN2NPC1
SCHEMBL7881981 0.80 SRD5A2 (0.45) GAAKDM4EALOX5ALDH1A1SMN1; SMN2
SCHEMBL7877960 0.80 HPGD (0.45) POLBGAAKDM4EALOX5ALDH1A1
SCHEMBL6798270 0.80 PSEN1 (0.43) POLBGAAKDM4EALOX5ALDH1A1
SCHEMBL6797980 0.80 POLB (0.38) POLBGAAKDM4EALOX5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 POLB 1536/4885GAA 292/4885KDM4E 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.